Table 3.
Registered clinical trials of virus-specific T cells in solid organ transplantation
| ID | Cell Therapy | Targets | Indication | N | Solid organ transplant | Virus-specific T Lymphocyte Donor | Primary Endpoint | Site |
| NCT02779439 | CTL | CMV, EBV, ADV | Resistance to Rx >2 wk | 25 | Any | Allogeneic | Infusion related safety at 1 wk | Sydney |
| NCT02532452 | CTL | EBV, CMV, ADV, or BKV | Any Infection | 100 | Any | Allogeneic | Infusion related toxicity | Cincinnati |
| NCT03010332 | CTL | CMV | Intolerant to or failed Rx | N/A | Any | Allogeneic (ATA230) | N/A | Atara Biotherapeutics |
| NCT03950414 | CTL | CMV | Intolerant to or failed Rx | 20 | Kidney | Allogenic | Safety and tolerability | Madison, Wisconsin |
CTL, cytotoxic T lymphocytes; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ADV, adenovirus.